The global autoimmune disease diagnostics market is
expected to reach a value of USD 5.0 billion by 2025, based on a new report by
Grand View Research, Inc. Government organizations along with related
associations strive to curb such high healthcare costs and simultaneously
provide improved diagnostic and therapeutic solutions to the patients. This has
resulted in increased funding by the NIH for R&D programs related to
autoimmune diseases.
Moreover, presence of favorable
government initiatives aimed at curbing incidence of these diseases and
developing viable diagnostic & treatment options is expected to drive
market growth over the forecast period.
Growing volume of autoimmune
diagnostic procedures has heightened the need for instruments and facilities
rendering faster and effective results. In an attempt to cater to
ever-increasing procedure volumes, diagnostic laboratories are rapidly moving
toward automation. Lab automation helps decrease workload via rapid turnaround
times and helps generate standardized & reproducible results.
Browse full research report on Global Autoimmune Disease Diagnostics Market: http://www.grandviewresearch.com/industry-analysis/autoimmune-disease-diagnostics-industry
Further key findings from
the study suggest:
- Localized autoimmune disease diagnostics was the largest segment in 2015 owing to high usage for type 1 diabetes and idiopathic thrombocytopenic purpura
- Type 1 diabetes is estimated to grow at a significant growth rate of over 4.0% in localized disease type segment
- Systemic disease diagnostics is anticipated to witness lucrative CAGR of around 5.0% over the forecast period due to increasing R&D for the development of novel diagnostic biomarkers for the treatment of rheumatoid arthritis and systemic lupus erythematosus
- Rheumatoid arthritis is one of the most recurring autoimmune disorders further demanding high amount of rapid diagnostics for exploring better alternative treatments
- North America was the largest regional market in 2015. High market penetration rate of technologically advanced products and increased lab automation rate are some of the factors contributing to its large share
- Asia Pacific region is anticipated to grow at the fastest CAGR of above 4.0% over the forecast period owing to increasing focus on type 1 diabetes diagnosis
- Some of the key players of this market include F. Hoffmann-La Roche Ltd; Siemens Healthineers; Abbott Laboratories; Beckman Coulter, Inc.; SQI Diagnostics; Quest Diagnostics; EUROIMMUN AG; AESKU. Diagnostics; Inova Diagnostics, Inc.; Crescendo Bioscience, Inc.; bioMerieux SA; Bio-Rad Laboratories, Inc.; and Hemagen Diagnostics, Inc.
Grand View Research has segmented the autoimmune disease
diagnostics market by type and region:
Autoimmune Disease Diagnostics Type Outlook (Revenue, USD
Million, 2014 - 2025)
- Systemic autoimmune disease diagnostics
- Rheumatoid arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus (SLE)
- Others
- Localized autoimmune disease diagnostics
- Multiple sclerosis
- Type 1 diabetes
- Hashimoto's Thyroiditis
- Idiopathic thrombocytopenic purpura
- Others
Autoimmune Disease Diagnostics Regional Outlook (Revenue,
USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- India
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment